BMS-986504 (MTRX1719) is the second generation of MTA-cooperative PRMT5 inhibitors designed to preferentially bind to the PRMT5-MTA complex which accumulates in cancer cells with MTAP deletion [38]. Here, MTAP is linked to cancer.